07.25.13
Roche
1H Revenues: CHF 23.3 billion (+4%)
1H Earnings: CHF 6.0 billion (+40%)
Comments: Pharmaceuticals Division sales were 18.1 billion Swiss francs (CHF), up 4%. HER2 franchise grew 11% (CER) to 3.3 billion with successful launches of Perjeta and Kadcyla. Avastin sales were up 12% to 3.1 billion. Diagnostics Division sales were 5.1 billion, up 2%. Significant restructuring charges relating to the closure of the Nutley, NJ site were incurred in 2012.
1H Revenues: CHF 23.3 billion (+4%)
1H Earnings: CHF 6.0 billion (+40%)
Comments: Pharmaceuticals Division sales were 18.1 billion Swiss francs (CHF), up 4%. HER2 franchise grew 11% (CER) to 3.3 billion with successful launches of Perjeta and Kadcyla. Avastin sales were up 12% to 3.1 billion. Diagnostics Division sales were 5.1 billion, up 2%. Significant restructuring charges relating to the closure of the Nutley, NJ site were incurred in 2012.